Minerva Imaging ApS

Building on more than two decades of research in Nuclear Medicine we are proficient in conducting molecular imaging studies with a translational focus.
Imaging studies can be combined with our advanced oncology models to investigate the in vivo biodistribution, e.g. radiolabeled antibodies, or imaging biomarkers in drug efficacy studies.

We facilitate clinical translation (Phase I/II) of radio-tracers in collaboration with our clinical partners.

Capabilities:

Available radiotracers:

18F-FDG, 18F-FLT, 18F-FET, 18F-NaF, 18F-FES
68Ga-PSMA, 68Ga-RGD
64Cu-DOTATATE
89Zr labeled antibodies, e.g. 89Zr-trastuzumab
Custom radiolabeling of small molecules, peptides, proteins and antibodies using e.g. 89Zr.

Imaging modalities:

PET/CT imaging
SPECT/CT imaging
MR imaging
Optical (bioluminescence) imaging

We have extensive experience in design and execution of pre-clinical studies for drug development within oncology and immuno-oncology. We can perform studies with cell line based models as well as PDX models available through the START-MINERVA collaboration. Studies can be designed to take advantage of our capabilities of orthotopic and metastatic models, external radiation therapy, and advanced non-invasive imaging.

Our capabilities

• Subcutaneous xenograft models (rats and mice)
  
• Targeted radionuclide therapy
  
• Orthotopic xenograft models
  
• PET/CT imaging
  
• Subcutaneous and orthotopic syngeneic models
  
• SPECT/CT imaging
  
• PDX models, including orthotopic implantation
  
• MR imaging
  
• External radiation therapy
  
• Optical (bioluminescence) imaging

We have a strong focus on imaging of pathophysiology in cardiovascular disease. Using relevant animals models of cardiovascular disease and longitudinal study designs we can follow therapeutic interventions by non-invasive imaging. Studies can be designed to take advantage of in-depth capabilities of microsurgery to establish e.g. myocardial infarction and ischemia-reperfusion models in rodents and larger species. Also, we have a long track record of using PET/CT imaging to monitor vascular inflammation in atherosclerosis.

Capabilities:

• Myocardial infarction models
  
• Ischemia-reperfusion models
  
• Atherosclerosis models
  
• Perfusion imaging PET/CT, SPECT/CT and MRI
  
• Cardiac function, ejection fraction by MRI and SPECT/CT
  
• Imaging of vascular inflammation by PET/CT
  
• Ex vivo quantification of disease

Oncology Animal Models Services

Animal Models of Disease Services

Animal Models and Studies Services

Drug Discovery & Development Services

Animal Imaging Services

Animal Model in vivo Analyses Services

Patient Derived Xenograft (PDX) Services

Nuclear imaging Services

Radiography Services

Imaging & Spectroscopy Services

We have substantial experience in performing studies with targeted radionuclide therapy in oncology. Our capabilities include testing of alpha- as well as beta-emitting ligands in subcutaneous, orthotropic or metastatic cancer models.

We facilitate clinical translation into Phase I studies including clinical trial design and execution in collaboration with our clinical partners.

Capabilities:

• Approval of handling alpha- and beta-emitters, e.g. 177Lu, 131I, 227Th
  
• Targeted radionuclide therapy in subcutaneous and orthotopic PDX models
  
• Targeted radionuclide therapy in metastatic models
  
• Custom radiolabeling of small molecules, peptides, proteins and antibodies

Chemistry and Materials Services